Examkin

Soru

Zorluk: Çok zorSubstance-Related and Addictive Disorders

A 34-year-old woman with a history of severe opioid use disorder has been receiving methadone maintenance therapy at a specialized clinic for the past two years. Her current daily dose is 80 mg, and she has maintained abstinence from illicit opioids. Due to a recent job offer in a rural area without access to a methadone clinic, she requests to transition to office-based buprenorphine/naloxone therapy. Arrange the following steps in the most appropriate chronological sequence for safely transitioning this patient from methadone to buprenorphine therapy.

  1. 1Gradually taper the daily methadone dose to 30-40 mg over several weeks.
  2. 2Discontinue methadone completely and abstain from all opioids for 36 to 72 hours.
  3. 3Evaluate for objective signs of moderate-to-severe opioid withdrawal (e.g., COWS score > 12).
  4. 4Administer an initial low test-dose of buprenorphine/naloxone.
  5. 5Up-titrate the buprenorphine/naloxone dosage over consecutive days until cravings and withdrawal are fully suppressed.

Cevap

The correct sequence is to first taper the methadone dose, then discontinue it for 36-72 hours, assess for objective signs of moderate-to-severe withdrawal, administer the initial buprenorphine test-dose, and finally up-titrate to a maintenance dose.
Transitioning a patient from methadone (a long-acting full mu-opioid agonist) to buprenorphine (a high-affinity partial agonist) carries a significant risk of precipitated withdrawal. The standard induction protocol involves first tapering the methadone to a lower dose (typically 30-40 mg daily) to decrease tissue stores. Next, methadone must be stopped completely for 36 to 72 hours due to its long half-life. Before administering buprenorphine, the clinician must confirm that the patient is in moderate-to-severe withdrawal (e.g., Clinical Opiate Withdrawal Scale [COWS] score > 12), indicating that sufficient mu-receptors are vacant. Only then can the initial test-dose of buprenorphine be given, followed by daily up-titration to a maintenance dose that suppresses cravings.

Adım Adım Çözüm

1
Recall the pharmacological differences between methadone and buprenorphine.
Methadone is a long-acting full mu-opioid agonist, while buprenorphine is a partial agonist with very high receptor affinity.
Administering buprenorphine while methadone is still bound to receptors will displace the methadone and precipitate severe withdrawal.
2
Determine the first clinical step to safely clear methadone from the patient's system.
The baseline methadone dose must first be tapered to 30-40 mg/day.
Tapering reduces the total body store of this highly lipophilic drug, making the subsequent transition safer and more tolerable.
3
Determine the required washout period.
Methadone must be discontinued completely for 36-72 hours.
Methadone's long half-life necessitates a longer washout period compared to short-acting opioids like heroin (which only require 12-24 hours).
4
Identify the clinical threshold required prior to buprenorphine induction.
Objective signs of moderate-to-severe withdrawal (e.g., COWS > 12) must be present.
Confirming significant withdrawal ensures that the mu-opioid receptors are sufficiently vacant to accept a partial agonist.
5
Sequence the final pharmacological induction steps.
Administer the initial test-dose of buprenorphine, followed by daily titration.
A low initial test-dose assesses patient tolerance without precipitating massive withdrawal, and subsequent titration achieves the required therapeutic maintenance level.

Anahtar Kavram

Buprenorphine is a high-affinity partial mu-opioid agonist that can precipitate severe withdrawal if administered before a full agonist has sufficiently cleared from the receptors. Transitioning from methadone requires tapering the dose, a 36-72 hour washout period, confirmation of moderate-to-severe withdrawal, and careful induction.
Bu soruyu puanla

Konular

Substance-Related and Addictive Disorders

Bu konudan daha fazla soru